Payment overview · 2025
General Payments
$108.95
6 reported records · 6 companies
Healthcare provider profile · identity verified
Thomas W. Fagg, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · JEFFERSON, IA · NPI 1235127481
Verified facts
What the public records show
CMS Open Payments records show Thomas W. Fagg, D.O. received $108.95 in general payments during 2025 across 6 reported records.
Insulet Corporation accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $24.14 | 22.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.85 | 19.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.02 | 16.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.37 | 15.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.55 | 14.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.02 | 12.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $108.95 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 153 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 68 |
| Lisinopril | Lisinopril | 343 | 77 |
| Omeprazole | Omeprazole | 301 | 71 |
| Gabapentin | Gabapentin | 240 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 62 |
| Furosemide | Furosemide | 192 | 39 |
| Metformin Hcl Er | Metformin Hcl | 188 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 42 |
| Losartan Potassium | Losartan Potassium | 163 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 39 |
| Jardiance | Empagliflozin | 153 | 26 |
| Tramadol Hcl | Tramadol Hcl | 149 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 39 |
| Ozempic | Semaglutide | 142 | 18 |
| Potassium Chloride | Potassium Chloride | 136 | 28 |
| Metformin Hcl | Metformin Hcl | 131 | 32 |
| Trazodone Hcl | Trazodone Hcl | 129 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 42 |
| Simvastatin | Simvastatin | 108 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 23 |
| Prednisone | Prednisone | 88 | 48 |
| Montelukast Sodium | Montelukast Sodium | 86 | 17 |
| Eliquis | Apixaban | 85 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 15 |
| Alendronate Sodium | Alendronate Sodium | 76 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 13 |
| Sertraline Hcl | Sertraline Hcl | 75 | 18 |
| Warfarin Sodium | Warfarin Sodium | 75 | suppressed |
| Allopurinol | Allopurinol | 67 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 12 |
| Famotidine | Famotidine | 62 | 12 |
| Buspirone Hcl | Buspirone Hcl | 60 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 11 |
| Alprazolam | Alprazolam | 59 | 13 |
| Atenolol | Atenolol | 59 | 14 |
| Finasteride | Finasteride | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 16 |
| Lorazepam | Lorazepam | 55 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 11 |
| Ezetimibe | Ezetimibe | 52 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 48 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | 13 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Ondansetron Odt | Ondansetron | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | 11 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 13 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Creon | Lipase/Protease/Amylase | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 22 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Trospium Chloride | Trospium Chloride | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 14 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $108.95 · 6 records | Insulet Corporation | CAMZYOS, CAPLYTA, JARDIANCE, Omnipod, UBRELVY, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error